A5030657714- Mesenchymal stem cell research
- Hematopoietic Stem Cell Transplantation
- Biomedical Ethics and Regulation
- CAR-T cell therapy research
- Pluripotent Stem Cells Research
- Periodontal Regeneration and Treatments
- Bone and Joint Diseases
- Orthopaedic implants and arthroplasty
- Cytomegalovirus and herpesvirus research
- Blood transfusion and management
- 3D Printing in Biomedical Research
- Cancer Cells and Metastasis
- Osteoarthritis Treatment and Mechanisms
- Virus-based gene therapy research
- Hematological disorders and diagnostics
- Neonatal Respiratory Health Research
- Biosimilars and Bioanalytical Methods
- Polyomavirus and related diseases
- Bone fractures and treatments
- Innovative Microfluidic and Catalytic Techniques Innovation
- Tissue Engineering and Regenerative Medicine
- Spine and Intervertebral Disc Pathology
- CRISPR and Genetic Engineering
- Medical Imaging and Analysis
- Full-Duplex Wireless Communications
Vall d'Hebron Institut de Recerca
2018-2024
Universitat Autònoma de Barcelona
2007-2024
Banc de Sang i Teixits
2015-2024
Vall d'Hebron Hospital Universitari
2024
Universitat Pompeu Fabra
2016
Tecnológico de Monterrey
2007
Background: The selection of assays suitable for testing the potency clinical grade multipotent mesenchymal stromal cell (MSC)-based products and its interpretation is a challenge both developers regulators. Here, we present bioprocess design production Wharton’s jelly (WJ)-derived MSCs validated immunopotency assay approved by competent regulatory authority batch release together with study failure modes in potential impact on critical quality attributes (CQA) final product. Methods:...
Cryopreservation was recommended to ensure continuity of unrelated donor (UD) hematopoietic stem cell transplantation (HSCT) during COVID-19 pandemic. However, its impact on clinical outcomes and feasibility not well known. We compared 32 patients who underwent UD HSCT using cryopreserved peripheral blood cells (PBSC) the pandemic with fresh PBSC in previous period. Median neutrophil engraftment 17.5 17.0 days grafts, respectively. Non-significant delays were found platelet recovery (25.5...
Abstract Background The increasing number of clinical trials for induced pluripotent stem cell (iPSC)-derived therapy products makes the production on grade iPSC more and relevant necessary. Cord blood banks are an ideal source young, HLA-typed virus screened starting material to produce HLA-homozygous lines wide immune-compatibility allogenic approaches. such (haplolines) involves particular attention all steps since donor informed consent, procurement a GMP-compliant isolation process....
Most public cord blood (CB) banks currently discard more than 80% of umbilical CB units not suitable for hemopoietic stem cell transplant due to low count. Although platelets, plasma, and red cells have been used experimental allogeneic applications in wound healing, corneal ulcer treatment, neonatal transfusion, no standard procedures their preparation defined internationally.A network 12 Spain, Italy, Greece, the UK, Singapore developed a protocol validate procedure routine production...
Prematurity is a significant health issue due to its incidence and associated complications. Anemia common in extremely preterm infants (EPI) often requires transfusions. Red blood cells (RBC) from adult (AB) donors have been linked oxygen-related complications EPI, leading the exploration of cord (CB) as an alternative source. However, standardization CB-RBC manufacturing comparison with AB-RBC characteristics are necessary before clinical studies can be conducted.
Pseudoarthrosis is a relatively frequent complication of fractures, in which the lack mechanical stability and biological stimuli results failure bone union, most frequently humerus tibia. Treatment recalcitrant pseudoarthrosis relies on achievement satisfactory combined with adequate local biology. Herein we present two cases atrophic that received tissue-engineering product (TEP) composed autologous marrow-derived mesenchymal stromal cells (BM-MSC) deantigenized trabecular particles from...
Cytomegalovirus encephalitis is a challenging life-threatening complication following hematopoietic stem cell transplantation for which medical treatment usually ineffective or toxic. However, in recent years, adoptive T-cell therapy has been reported to provide significant chance of cure patients with viral infections. Herein, two cases pediatric successfully treated third-party donor-derived virus-specific T cells CMV meningoencephalitis are reported.
Background There are many advantages to using cord blood (CB) as a source of therapeutic platelet and plasma derivatives for regenerative medicine. These include availability, universal use, young donor source, virally safe biological material, rich in tissue factors. Materials methods We aimed validate bioprocess design the production blood-derived concentrates (CBPC) public Cord Blood Bank (CBB). CBPC was defined product 10±5 mL, 1,000±200×109/L total platelets, free erythrocytes...
Abstract Multipotent mesenchymal stromal cells (MSC) offer new therapeutic opportunities based on their ability to modulate an imbalanced immune system. Immunomodulatory potency is typically demonstrated in vitro by measuring the presence of surrogate markers (i.e., indoleamine-2,3-dioxygenase, IDO; tumor necrosis factor receptor type 1, TNFR1) and/or functional assays co-cultures inhibition lymphoproliferation, polarization macrophages). However, biological variability reagents used latter...
Background Gonarthrosis is the most common cause of pain and disability in middle-aged elderly people [1,2]. The lack long-lasting effective treatments for repairing degenerated articular cartilage has spurred research into novel cell-based therapies aiming at reducing pain, slowing degeneration and, ultimately, reverting natural history osteoarthritis (OA) [3]. Herein we report development a mesenchymal stromal cell (MSC)-based therapy, from conception up to completion Phase I/IIa...
The increasing demand of clinical-grade mesenchymal stromal cells (MSCs) for use in advanced therapy medicinal products (ATMPs) require a re-evaluation manufacturing strategies, ensuring scalability from two-dimensional (2D) surfaces to volumetric (3D) productivities. Herein we describe the design and validation Good Manufacturing Practice-compliant 3D culture methodology using microcarriers 3-L single-use stirred tank bioreactors (STRs) expansion Wharton's jelly (WJ)-derived MSCs accordance...
Adoptive cell therapy (ACT) of ex vivo expanded tumor-infiltrating lymphocytes (TILs) can mediate objective tumor regression in 28%-49% metastatic melanoma patients. However, the efficacy TIL most epithelial cancers remains limited. We present design a phase I clinical study that aims to assess safety and NEXTGEN-TIL, product selected based on neoantigen recognition, patients with advanced tumors immune checkpoint blockade (ICB)-resistant solid tumors. Pre-rapid expansion protocol (REP)...